AU2003275044A8 - Methods for assessing the ability of hiv patients to restrict hiv replication - Google Patents

Methods for assessing the ability of hiv patients to restrict hiv replication

Info

Publication number
AU2003275044A8
AU2003275044A8 AU2003275044A AU2003275044A AU2003275044A8 AU 2003275044 A8 AU2003275044 A8 AU 2003275044A8 AU 2003275044 A AU2003275044 A AU 2003275044A AU 2003275044 A AU2003275044 A AU 2003275044A AU 2003275044 A8 AU2003275044 A8 AU 2003275044A8
Authority
AU
Australia
Prior art keywords
hiv
assessing
ability
methods
restrict
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003275044A
Other versions
AU2003275044A1 (en
Inventor
Stephen A Migueles
Mark Connors
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2003275044A1 publication Critical patent/AU2003275044A1/en
Publication of AU2003275044A8 publication Critical patent/AU2003275044A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003275044A 2002-09-20 2003-09-22 Methods for assessing the ability of hiv patients to restrict hiv replication Abandoned AU2003275044A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41202002P 2002-09-20 2002-09-20
US60/412,020 2002-09-20
PCT/US2003/029549 WO2004027034A2 (en) 2002-09-20 2003-09-22 Methods for assessing the ability of hiv patients to restrict hiv replication

Publications (2)

Publication Number Publication Date
AU2003275044A1 AU2003275044A1 (en) 2004-04-08
AU2003275044A8 true AU2003275044A8 (en) 2004-04-08

Family

ID=32030781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003275044A Abandoned AU2003275044A1 (en) 2002-09-20 2003-09-22 Methods for assessing the ability of hiv patients to restrict hiv replication

Country Status (2)

Country Link
AU (1) AU2003275044A1 (en)
WO (1) WO2004027034A2 (en)

Also Published As

Publication number Publication date
WO2004027034A2 (en) 2004-04-01
AU2003275044A1 (en) 2004-04-08
WO2004027034A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
HK1096083A1 (en) Sulfonamide derivatives for the treatment of diseases
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
HK1146061A1 (en) Nucleoside phosphonates and analogs thereof for the treatment of hpv- infections
IL163731A0 (en) Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
PT1487828E (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
AU2003290939A8 (en) Replication of biological tiussue
FR2848817B1 (en) TRICOUCHE THERAPEUTIC MATTRESS FOR PATIENTS OBESES
AU2003284942A8 (en) Oral extended release tablets and methods of making and using the same
AU2003275044A8 (en) Methods for assessing the ability of hiv patients to restrict hiv replication
GB2388027B (en) Use of palatinose for the treatment of mental stress
GB0209254D0 (en) Preparation for the relief of disease
EP1767210A4 (en) The medical use of paeoniflorin
GB2410744B (en) Kinase inhibitors for the treatment of disease
GB0201025D0 (en) The treatment of degenerative diseases
AU2003287388A8 (en) Inhibition of hiv-1 replication
PL371269A1 (en) 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, the use thereof for producing drugs used in the treatment of immunological diseases
AU2003297912A1 (en) Methods for screening compounds for use in the treatment of disease
AU2003274911A8 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003294499A8 (en) Rhebs as modifiers of the rb pathway and methods of use
GB0406387D0 (en) Sulfonamide derivatives for the treatment of diseases
IL176564A0 (en) Sulfonamide derivatives for the treatment of diseases
GB0406388D0 (en) Sulfonamide derivatives for the treatment of diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase